Maria Törnsén

Maria Törnsén is President North America for Calliditas Therapeutics, where she is responsible for leading the company’s US operations, including commercial and medical affairs. Prior to Calliditas, Ms. Törnsén was Chief Commercial Officer at Passage Bio from 2021-2022, where she was responsible for leading and building out the company’s commercial organization and strategy, including determining product positioning and paths to commercialization. From 2019 to 2021, Ms. Törnsén served as Senior Vice President and General Manager of Sarepta Therapeutics’ U.S. Commercial organization, including market access, trade & distribution, reimbursement, sales, patient services and marketing. From 2017 to 2019, she was Vice President, Global Therapeutic Area Head of rare neurological, metabolic and endocrine diseases at Sanofi Genzyme, where she managed a $1.6 B portfolio with five marketed and three pipeline products, and was commercial lead on multiple alliances. From 2011 to 2017, Ms. Törnsén held advancing commercialization roles in the endocrine and rare diseases groups at Shire, rising to the role of Vice President, Head of Endocrine Rare Disease Sales, U.S. Commercial. Earlier in her career, she gained experience in global marketing and as a Product Specialist at Merck KGaA and Eli Lilly, respectively.

Ms. Törnsén earned a Master of Science (MSc) in International Business Administration from Lund University, Sweden.

Ms. Törnsén has been a member of Immunic’s Board since July 2022. She serves on the Audit Committee and the Compensation Committee.